Severe Pneumonia
32
4
6
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.1%
1 terminated out of 32 trials
90.9%
+4.4% vs benchmark
6%
2 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (32)
A Prospective Observational Cohort Study Protocol for Disease Severity Stratification and Prognosis Assessment in Patients With Pneumonia
AI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia
Rapid Identification of Infectious Pathogens in Severe Pneumonia Guided by Bronchoscopic Imaging and Lung CT
Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia)
Fiberoptic Bronchoscopy in Severe Ventilator-associated Pneumonia
Lung Response to a Higher PEEP During Severe Pneumonia: a CT Study
Diagnostic Application of AI-ROSE in Severe Pneumonia
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study
Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia(the HSV-SP Study)
Species-specific Bacterial Detector for Fast Pathogen Diagnosis of Severe Pneumonia
Enhancing Pediatric Acute Care Through Adaptive E-Learning and In-Person Skills Practice in Tanzania
Dynamic Pattern of Etiology, Immunoinflammatory Factors and Their Association With Prognosis of Severe Pneumonia
Rapid Diagnosis of Severe Respiratory Tract Infectious Diseases and Screening of Biomarkers for Stratified Diagnosis
Fulminant Severe CAP - an Observational Study
The Application of Different Sedation Protocols in ICU Patients With Severe Pneumonia
Detection and Characterization of Lower Respiratory Infections in Critically Ill Patients
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
Feasibility and Acceptability Followed by Effectiveness of bCPAP for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia
Research on the Treatment of Severe Community-acquired Pneumonia in Children